Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:CHMANASDAQ:PHVSNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.28-3.2%$4.74$3.26▼$8.06$784.76M0.764.39 million shs5.10 million shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsPHVSPharvaris$16.07-0.2%$15.35$11.51▼$25.50$840.30M-2.8574,186 shs123,891 shsZYMEZymeworks$11.25-3.1%$11.81$8.21▼$17.70$782.74M1.24598,558 shs337,596 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-3.24%-11.35%-28.23%-42.05%-57.89%CHMAChiasma0.00%0.00%0.00%0.00%0.00%PHVSPharvaris-0.25%-6.02%+27.34%-7.48%-22.74%ZYMEZymeworks-3.10%-0.71%+2.27%-23.05%+25.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.4584 of 5 stars4.52.00.04.41.92.50.6CHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/APHVSPharvaris1.2755 of 5 stars3.51.00.00.01.90.80.0ZYMEZymeworks2.3194 of 5 stars3.40.00.00.02.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39216.73% UpsideCHMAChiasma 0.00N/AN/AN/APHVSPharvaris 3.00Buy$40.67153.06% UpsideZYMEZymeworks 2.88Moderate Buy$21.0086.67% UpsideCurrent Analyst Ratings BreakdownLatest CHMA, PHVS, ARDX, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.004/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.003/12/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.003/7/2025ARDXArdelyxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/7/2025ARDXArdelyxLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$11.003/7/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $19.003/4/2025ARDXArdelyxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.17N/AN/A$0.73 per share4.49CHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36PHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/AZYMEZymeworks$93.38M8.38N/AN/A$6.63 per share1.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A10.58N/A-11.73%-24.87%-10.51%N/ACHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/APHVSPharvaris-$109.18M-$2.68N/AN/AN/AN/A-38.52%-36.69%N/AZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%N/ALatest CHMA, PHVS, ARDX, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A2/20/2025Q4 2024ARDXArdelyx$0.02$0.02N/A$0.02$111.16 million$116.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31CHMAChiasmaN/A7.917.08PHVSPharvarisN/A19.0819.08ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%CHMAChiasma61.68%PHVSPharvarisN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.90%CHMAChiasma8.30%PHVSPharvaris11.84%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableCHMAChiasma8557.89 millionN/ANot OptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableZYMEZymeworks46069.58 million67.56 millionOptionableCHMA, PHVS, ARDX, and ZYME HeadlinesRecent News About These CompaniesSchonfeld Strategic Advisors LLC Buys Shares of 22,800 Zymeworks Inc. (NYSE:ZYME)May 15 at 3:44 AM | marketbeat.comWall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a BetMay 14 at 11:01 AM | zacks.comAnalyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging HigherMay 14 at 7:17 AM | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Granahan Investment Management LLCMay 12 at 6:35 AM | marketbeat.comFarallon Capital Management LLC Sells 31,026 Shares of Zymeworks Inc. (NYSE:ZYME)May 11, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)May 11, 2025 | marketbeat.comZymeworks May 2025 slides: Pipeline expansion amid modest revenue growthMay 10, 2025 | investing.comZymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster PresentationsMay 10, 2025 | nasdaq.comZymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comZymeworks Inc. (NYSE:ZYME) Shares Bought by Voya Investment Management LLCMay 10, 2025 | marketbeat.comZymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finanznachrichten.deZymeworks outlines robust pipeline advancements and financial resilience through 2027May 10, 2025 | msn.comZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finance.yahoo.comZymeworks Inc. (ZYME) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZymeworks Inc. 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comZymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comBlackstone Inc. Has $8.34 Million Stock Position in Zymeworks Inc. (NYSE:ZYME)May 8, 2025 | marketbeat.comRaymond James Financial Inc. Takes $888,000 Position in Zymeworks Inc. (NYSE:ZYME)May 8, 2025 | marketbeat.comJazz Pharmaceuticals Stock Price, Quotes and ForecastsMay 7, 2025 | benzinga.comZymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.comZymeworks (ZYME) Projected to Post Earnings on ThursdayMay 6, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long2 Healthcare Recession-Resistant Stocks Unaffected by TariffsBy Jea Yu | April 15, 2025View 2 Healthcare Recession-Resistant Stocks Unaffected by TariffsCHMA, PHVS, ARDX, and ZYME Company DescriptionsArdelyx NASDAQ:ARDX$3.28 -0.11 (-3.24%) As of 05/14/2025 04:00 PM EasternArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Chiasma NASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Pharvaris NASDAQ:PHVS$16.07 -0.04 (-0.25%) As of 05/14/2025 04:00 PM EasternPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Zymeworks NYSE:ZYME$11.25 -0.36 (-3.10%) As of 05/14/2025 04:00 PM EasternZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
